Dividends & Buybacks ·
Enlivex approves 1-for-16 reverse share split effective October 27
ENLVEnlivex Ltd.
Shareholders approved a 1-for-16 reverse stock split, reducing authorized shares from 158.3 million to 9.9 million and outstanding shares from approximately 24.5 million to roughly 1.5 million. The split becomes effective on October 27, 2026, with trading beginning on a split-adjusted basis under the symbol ENLV. Fractional shares will be rounded up to the nearest whole share, and warrant and option exercise prices will adjust proportionately. Enlivex is a longevity company developing Allocetra immunotherapy for age-related osteoarthritis while operating a prediction markets treasury.